New findings may help patients with low to moderate risk of tumor lysis syndrome while reducing the burden for hematologists.

Several studies have been conducted, but questions remain about where such therapies will fit into multiple myeloma treatment ...

The study highlights the importance of including patient self-assessment—and not just clinician assessment—when planning ...

“The 340B statute does not permit drug companies to unilaterally withhold discounts from 340B hospitals in exchange for the surrender of purchase data or what are, in essence, pre-payment audits. The ...

The most common surgical complications in obese patients with epithelial ovarian cancer (EOC) include wound infection, ...

Astrasentan becomes the first and only endothelin A receptor antagonist to focus on proteinuria reduction in primary ...

Amid growing legislative pressures and industry debates, pharmacy benefit managers (PBMs) are exploring new strategies to ...

Countries located in sub-Saharan Africa would be most affected by all funding cuts to the international HIV response.

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish ...

Kimberly Westrich, MA, chief strategy officer at the National Pharmaceutical Council, discusses the importance of clearly defining the role of patient representatives on pharmacy-and-therapeutics and ...

Dan Nardi, MS, CEO of Reimagine Care, claims that on-demand cancer treatment via telehealth is the future of oncology care delivery.

Laura Bobolts, PharmD, BCOP, senior vice president of clinical strategy and growth at OncoHealth, discusses strategies for managing costs of novel cellular and gene therapies in the oncology pipeline.